Prolonged Cardiac ECG Patch Versus Conventional Holter For Detecting Atrial Fibrillation After Cerebral Ischemic Event
NCT ID: NCT05082467
Last Updated: 2025-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
320 participants
OBSERVATIONAL
2021-01-12
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Smartphone Electrocardiogram for Recording Atrial Fibrillation After a Cerebral Ischemic Event
NCT04332718
Using 14-day Continuous Electrocardiography Patch Monitoring to Detect Paroxysmal Atrial Fibrillation After Stroke
NCT05218473
Differences in ECG- vs. proLonged cardIac MonItor-DeTected Atrial Fibrillation in STROKE Patients (DELIMIT AF-STROKE)
NCT05822791
30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event
NCT00846924
Continuous EKG Monitoring Using S-Patch Ex : Prospective Observational Study (S-patch Registry)
NCT05119725
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OBJECTIVES:
Primary objective:
To determine the diagnostic yield of a cardiac ECG patch compared to conventional Holter monitor for detecting occult paroxysmal atrial fibrillation (AF) within 24 hours in patients admitted with acute ischemic stroke or transient ischemic attack (TIA) of undetermined etiology after completion of a standard clinical stroke work-up.
Secondary objective(s):
* To determine efficacy of prolonged 7-day ambulatory ECG monitoring (using cardiac ECG patch) compared to conventional 24-hour ambulatory ECG monitoring (using conventional Holter) strategies in detecting paroxysmal AF.
* To determine if a strategy of a prolonged 7-day ambulatory ECG monitoring results in a change in clinical practice, i.e., more patients are anticoagulated.
* To assess the time to the first detection of AF within the first 7 days of monitoring.
Exploratory objective(s):
* To identify predictors of occult AF based on clinical, neuroimaging, echocardiography, and ECG features.
* To assess feasibility and cost-effectiveness of 7-day cardiac ECG patch monitoring for detecting occult paroxysmal AF.
SCREENING:
* Written informed consent obtained from patient or guardian
* Inclusion/Exclusion criteria.
* Social demographics, Risk factors, Comorbidities, Admission Brain CT/MRI,Stroke status including date and time of index event, date and time of admission, admission modified Rankin scale/NIHSS Score \[Data extracted from patient records\].
* 12-lead ECG, Transthoracic Echocardiogram
Eligible patients will be enrolled in the study and proceed with a baseline assessment.
BASELINE ASSESSMENT:
* Concomitant medication, Oxfordshire classification of stroke and CHA2DS2VAS Score \[Data extracted from patient records\].
* Anthropometric measurements and vital signs assessments
* 24h Holter and 7d Cardiac ECG patch monitoring
FOLLOW UP VISITS:
Follow-up visits will occur at 3 months and 1 year for the efficacy and outcomes for the duration of the study. There will be a total of 2 visits.The investigator/study team will perform the following procedures at each visit where applicable:
* Clinical examination (NIHSS Score assessment)
* Review concomitant medications
* AE/SAE assessment and monitoring
* Outcomes assessment
* Health outcome interview with EQ-5D Questionnaire
* TOAST Classification (at 1 year follow up visit)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of acute ischemic stroke or transient ischemic attack (TIA) (WHO definition) of undetermined etiology made by neurologist within 7 days after the index event. The event must be either:
* an ischemic stroke confirmed by neuroimaging; or
* a TIA, defined as involving a focal unilateral motor deficit, speech/language deficit or hemianopia, with symptom duration \<24 hours (note: amaurosis fugax/ transient monocular blindness, pure sensory spells, isolated vertigo spells, etc. do not qualify for enrolment given the potential for misdiagnosis of such events).
3. No AF detected in baseline 12-lead ECG on admission.
4. The following diagnostic test have already been completed as part of clinical routine post-stroke/TIA:
* Brain imaging with CT or MRI,
* Transthoracic echocardiography to congenital heart disease and endocarditis.
Exclusion Criteria
2. Modified Rankin Scale ≥5 on index admission.
3. Previous documented history of primary intracerebral bleeding.
4. Previous documented history of AF or atrial flutter (a remote history of transient AF during perioperative period is not exclusionary).
5. Skin allergies, conditions, or sensitivities to cardiac patch.
6. Exclusively retinal stroke or retinal TIA event.
7. Pre-existing indication for anticoagulation (eg. History of mechanical heart valve replacement, deep vein thrombosis).
8. Pre-existing contraindication for permanent anticoagulation (eg. hypocoagulable state).
9. Echocardiographic findings of congenital heart disease and endocarditis.
10. Indicated for pacemaker, implantable cardiac defibrillator (ICD), CRT device, or an implantable hemodynamic monitoring system.
11. Intravenous drug users (IVDUs).
12. Life expectancy \< 1 year for reasons other than stroke (eg. Metastatic cancer disease).
13. Concomitant participation in other clinical trials involving investigational medications.
14. Pregnancy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sarawak Heart Centre
OTHER
Ministry of Health, Malaysia
OTHER_GOV
Sarawak General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Diana Hui Ping Foo
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Diana Hui Ping Foo, MD
Role: PRINCIPAL_INVESTIGATOR
Sarawak General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sarawak General Hospital
Kuching, Sarawak, Malaysia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NMRR-19-3798-52441
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.